Is Afamin a novel biomarker for gestational diabetes mellitus? A pilot study
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In search of potential early biomarkers for timely prediction of gestational diabetes mellitus (GDM), we focused on afamin, a vitamin E-binding protein in human plasma.. Afamin plays a role in anti-apoptotic cellular processes related to oxidative stress and is associated with insulin resistance and other features of metabolic syndrome. During uncomplicated pregnancy its serum concentrations increase linearly. The aim of this study was to investigate the suitability of afamin as early marker for predicting GDM. METHODS: In a first-trimester cohort from a prospective observational study of adverse pregnancy outcomes we secondarily analyzed afamin concentrations in 59 patients diagnosed with GDM and 51 controls. Additionally, afamin concentrations were cross-sectionally examined in a mid-trimester cohort of 105 women and compared with results from a simultaneously performed oral glucose tolerance test (OGTT). Subgroup analysis comparing patients treated with either insulin (iGDM) or dietary intervention (dGDM) was performed in both cohorts. Patients were recruited at the University Hospital Essen, Germany, between 2003 and 2016. RESULTS: Results were adjusted for body-mass-index (BMI) and gestational age. First and mid-trimester cohorts yielded significantly elevated afamin concentrations in patients with pathological OGTT compared to patients without GDM (first trimester cohort: mean, 113.4 mg/l; 95% CI, 106.4-120.5 mg/l and 87.2 mg/l; 95% CI, 79.7-94.7 mg/l; mid-trimester cohort: mean, 182.9 mg/l; 95% CI, 169.6-196.2 mg/l and 157.3 mg/l; 95% CI, 149.1-165.4 mg/l, respectively). In the first-trimester cohort, patients developing iGDM later in pregnancy presented with significantly higher afamin concentrations compared to patients developing dGDM and compared to patients without GDM. In the mid-trimester cohort, mean concentrations of afamin differed significantly between patients with dGDM compared to controls and between patients with iGDM and controls. Patients with iGDM showed only slightly higher afamin levels compared to patients with dGDM. CONCLUSION: Afamin may serve as a new early biomarker for pathological glucose metabolism during pregnancy. Further research is needed to determine afamin's concentrations during pregnancy, its predictive value for early detection of pregnancies at high risk to develop GDM and its diagnostic role during the second trimester.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
International Association of Diabetes and Pregnancy Study Groups Consensus Panel (2010) · Diabetes Care · doi:10.2337/dc09-1848 · Cited by 5,390
Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes
Landon, M. B., Spong, C. Y., Thom, E., Carpenter, M. W., Ramin, S. M., Casey, B., Wapner, R. J., Varner, M. W., Rouse, D. J., Thorp, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902430 · Cited by 2,122
Criteria for screening tests for gestational diabetes
Carpenter, M. W., & Coustan, D. R. (1982) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(82)90349-0 · Cited by 1,924 · cited 3×
“Since 2011, the following definition is used in Germany to diagnose GDM: fasting glucose: 92 mg/dl, glucose after 1 h: 180 mg/dl, glucose after 2 h: 153 mg/dl [4, 9, 26].”
BackgroundMethodDiagnosis and classification of diabetes mellitus
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s062 · Cited by 1,817
TNF-α Is a Predictor of Insulin Resistance in Human Pregnancy
Kirwan, J. P., Hauguel-De Mouzon, S., Lepercq, J., Challier, J.-C., Huston-Presley, L., Friedman, J. E., Kalhan, S. C., & Catalano, P. M. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2207 · Cited by 738
PLYMATE, S. R., MATEJ, L. A., JONES, R. E., & FRIEDL, K. E. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-3-460 · Cited by 693 · cited 1×
“Additionally, insulin concentrations regulate the expression of sex hormone–binding protein (SHBG) in the liver [23] and low concentrations of SHBG during the first trimester of pregnancy may indicate the development of GDM [24].”
BackgroundCatalano, P. M., Huston, L., Amini, S. B., & Kalhan, S. C. (1999) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(99)70662-9 · Cited by 680
Cited by
Lorenzo-Almorós, A., Hang, T., Peiró, C., Soriano-Guillén, L., Egido, J., Tuñón, J., & Lorenzo, Ó. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0935-9 · Cited by 202
Gestational Diabetes Mellitus in Europe: A Systematic Review and Meta-Analysis of Prevalence Studies
Paulo, M. S., Abdo, N. M., Bettencourt-Silva, R., & Al-Rifai, R. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.691033 · Cited by 181
Biochemical and Molecular Biomarkers: Unraveling Their Role in Gestational Diabetes Mellitus
Karami, M., Mousavi, S. H., Rafiee, M., Heidari, R., & Shahrokhi, S. Z. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-00980-8 · Cited by 33
Metadata
- Authors
- Köninger, A., Mathan, A., Mach, P., Frank, M., Schmidt, B., Schleussner, E., Kimmig, R., Gellhaus, A., & Dieplinger, H.
- Venue
- Reproductive Biology and Endocrinology
- Published
- 2018-03-27
- Volume
- 16
- Issue
- 1
- Pages
- 30-30
- ISSN
- 1477-7827 (ISSN-L)
- OpenAlex
- W2795182964
- Cited by
- 53
- References
- 14
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is Afamin a novel biomarker for gestational diabetes mellitus? A pilot study. https://app.cochat.ai/papers/10.1186/s12958-018-0338-x
- The paper
- Köninger, A., Mathan, A., Mach, P., Frank, M., Schmidt, B., Schleussner, E., Kimmig, R., Gellhaus, A., & Dieplinger, H. (2018). Is Afamin a novel biomarker for gestational diabetes mellitus? A pilot study. Reproductive Biology and Endocrinology. https://doi.org/10.1186/s12958-018-0338-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.